	US 11,946,039 B2
	Class II, type II CRISPR systems
Brian Thomas, Emeryville, CA (US); Christopher Brown, Emeryville, CA (US); Audra Devoto, Emeryville, CA (US); Cristina Butterfield, Emeryville, CA (US); Lisa Alexander, Emeryville, CA (US); and Daniela S. A. Goltsman, Emeryville, CA (US)
Assigned to Metagenomi, Inc., Emeryville, CA (US)
Filed by Metagenomi, Inc., Emeryville, CA (US)
Filed on Jul. 5, 2022, as Appl. No. 17/857,923.
Application 17/857,923 is a continuation of application No. PCT/US2021/024945, filed on Mar. 30, 2021.
Claims priority of provisional application 63/116,149, filed on Nov. 19, 2020.
Claims priority of provisional application 63/003,159, filed on Mar. 31, 2020.
Prior Publication US 2023/0051396 A1, Feb. 16, 2023
Int. Cl. C12N 15/10 (2006.01); C12N 9/22 (2006.01); C12N 9/78 (2006.01); C12N 15/11 (2006.01); C12N 15/63 (2006.01)

CPC C12N 15/102 (2013.01) [C12N 9/22 (2013.01); C12N 9/78 (2013.01); C12N 15/11 (2013.01); C12N 15/63 (2013.01); C12N 2310/20 (2017.05)]

24 Claims

1. An engineered nuclease system comprising:

(a) an endonuclease comprising a RuvC-I domain and an HNH domain; and

(b) an engineered guide ribonucleic acid (RNA) structure capable of forming a complex with said endonuclease comprising:

(i) a guide RNA sequence capable of hybridizing to a target deoxyribonucleic acid (DNA) sequence; and

(ii) an RNA sequence capable of binding to said endonuclease, wherein said RNA sequence comprises a sequence with at least 90% sequence identity to nonvariable nucleotides of any one of SEQ ID NOs: 203, 202, 613, or 614,

wherein said endonuclease comprises a sequence with at least 70% sequence identity to SEQ ID NO: 2.